EYSINS, Switzerland, July 29, 2024 /PRNewswire/ -- AliveDx (“Company”) is proud to announce it has received IVDR CE mark for its groundbreaking microarray immunoassay, designed for the detection of a specific IgE directed to a protein allergen in human serum. This is the Company’s first product for the evaluation of allergies, enhancing its portfolio of products beyond autoimmunity.
This immunoassay, run on AliveDx’s proprietary MosaiQ® platform, is an important milestone for the current development of the Company’s multiplex immunoassay microarray, which aims to simultaneously detect 30+ allergens, including inhalant and food allergens.
The multiplex immunoassay microarray technology marks a significant advancement in diagnostics by enabling simultaneous testing for multiple conditions. This approach streamlines the identification process, simplifies laboratory workflows, and reduces the hands-on time required with singleplex methods. As a result, both laboratories and clinicians save valuable time and can detect and rule out various conditions more efficiently. For patients sensitized to multiple allergens (polysensitized), this technology targets a fast, thorough diagnosis and more targeted treatment.
“The new multiplex immunoassay will provide a detailed analysis of an individual’s allergic sensitization by testing specific IgE to a wide array of allergens in a single test. This comprehensive approach will help optimize laboratory workflows, and help clinicians obtain a complete picture of their patient’s atopic sensitization profile,” said Christian Fischer, Chief Scientific & Medical Officer at AliveDx.
The MosaiQ platform is already CE marked for autoimmune disease screening. Receiving a first IVDR CE mark in the Allergy category reaffirms AliveDx’s dedication to expanding its MosaiQ® offering and aiding the millions of people worldwide who suffer from allergies.
This milestone highlights the Company’s commitment to establishing itself as a key player in both the Allergy and Autoimmune sectors. It also underscores the flexibility and versatility of the MosaiQ platform. AliveDx anticipates expanding its panels in both segments in the coming months and partnering with distributors throughout the world.
“This is a memorable moment in the history of AliveDx. Patients will soon be able to receive results for multiple allergens from a single blood sample, reducing the need for multiple tests and visits. For the medical community, this means having access to an efficient and cost-effective solution, which consolidates multiple tests into one. We look forward to supporting patients around the world, and helping them get appropriate treatment sooner,” said Manuel O. Méndez, CEO of AliveDx.
About AliveDx
At AliveDx, our mission is to empower diagnostic insights, transform patient care, and innovate for life. With over 30 years in in-vitro diagnostics, we aim to advance the future of diagnostics worldwide. We prioritize the health of patients and create innovative solutions that enable laboratories and clinicians to shorten the time to diagnosis. Our brands aim to create both economical and clinical value. We achieve this by simplifying laboratory workflows and delivering fast and accurate results that streamline clinical decision-making. At AliveDx, we innovate for life. We collaborate with laboratorians, clinicians, patient advocacy groups, academic institutions, and industry partners. When we feel ‘alive’, we do more than just live. Feeling alive is giving purpose, meaning and energy to our communities, our work and ourselves.About the MosaiQ platform
MosaiQ® is a fully automated high-throughput platform that streamlines multiplex testing for Autoimmune, Allergy, and beyond. This intuitive platform delivers fast and accurate results using advanced microarray panels to rapidly detect and identify disease markers—maximizing workflow efficiencies, simplifying pathways, and helping shorten time to diagnosis.
For more information about AliveDx and its IVD solutions, please visit www.alivedx.com or connect with us on LinkedIn and X.
©AliveDx Suisse SA. 2024. The AliveDx logo, AliveDx and MosaiQ are trademarks or registered trademarks of AliveDx group companies in various jurisdictions. Menus and capabilities are subject to change. Not all methods may be available in all territories. Subject to regulatory clearance.
View original content:https://www.prnewswire.com/news-releases/alivedx-receives-ivdr-ce-mark-for-groundbreaking-microarray-immunoassay-in-allergy-diagnostics-302207838.html
SOURCE AliveDx
